View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 04, 2020
Document and Entity Information
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Entity Registrant Name	FENNEC PHARMACEUTICALS INC.
Trading Symbol	FENCF
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		25,356,034
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001211583
Amendment Flag	false

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 38,729	$ 13,650
Prepaid expenses	166	226
Other current assets	4	8
Total current assets	38,899	13,884
Non-current assets:
Deferred issuance costs	528	326
Amortization of deferred issuance costs	(111)	(64)
Total non-current assets	417	262
Total assets	39,316	14,146
Current liabilities:
Accounts payable	2,755	1,612
Accrued liabilities	435	659
Total current liabilities	3,190	2,271
Commitments and Contingencies (Note 7)
Stockholders' equity:
Common stock, no par value; unlimited shares authorized; 25,356 shares issued and outstanding (2019-19,896)	138,359	106,392
Additional paid-in capital	49,226	48,271
Accumulated deficit	(152,702)	(144,031)
Accumulated other comprehensive income	1,243	1,243
Total stockholders' equity	36,126	11,875
Total liabilities and stockholders' equity	$ 39,316	$ 14,146

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Condensed Consolidated Statements of Operations
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	1,121	1,969	2,514	3,640
General and administrative	3,724	2,844	6,166	3,853
Loss from operations	(4,845)	(4,813)	(8,680)	(7,493)
Other income (expense):
Other gain/(loss)	13	(10)	4	(10)
Amortization expense	(30)	(17)	(47)	(29)
Interest income and other	17	110	52	176
Total other income/(expense), net		83	9	137
Net loss	$ (4,845)	$ (4,730)	$ (8,671)	$ (7,356)
Basic net loss per common share	$ (0.21)	$ (0.24)	$ (0.40)	$ (0.37)
Diluted net loss per common share	$ (0.21)	$ (0.24)	$ (0.40)	$ (0.37)
Weighted-average number of common shares outstanding, basic	23,393	19,896	21,635	19,896
Weighted-average number of common shares outstanding, diluted	23,393	19,896	21,635	19,896

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating activities:
Net loss	$ (4,845)	$ (4,730)	$ (8,671)	$ (7,356)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred issuance cost	30	17	47	29
Stock-based compensation - contractors	21	331	42	374
Stock-based compensation - employees	522	1,669	913	1,890
Changes in operating assets and liabilities:
Prepaid assets	54	52	60	112
Other current assets	(2)	3	4
Accounts payable	1,080	(70)	1,143	196
Accrued liabilities	24	(28)	(403)	(480)
Net cash used in operating activities	(3,116)	(2,756)	(6,865)	(5,235)
Financing activities:
Issuance of shares, net of issuance costs	31,967	0	31,967	0
Capitalized deferred issuance cost	(23)	0	(23)	(71)
Net cash provided by financing activities	31,944	0	31,944	(71)
Increase/(decrease) in cash and cash equivalents	28,828	(2,756)	25,079	(5,306)
Cash and cash equivalents - Beginning of period	9,901	20,231	13,650	22,781
Cash and cash equivalents - End of period	38,729	17,475	38,729	17,475
Non-cash deferred issuance cost (warrant value)	$ 179	$ 0	$ 179	$ 255

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock Employee	Common Stock Contractors	Common Stock Consultants	Common Stock	Additional Paid-in Capital Employee	Additional Paid-in Capital Contractors	Additional Paid-in Capital Consultants	Additional Paid-in Capital	Accumulated Deficit Employee	Accumulated Deficit Contractors	Accumulated Deficit Consultants	Accumulated Deficit	Accumulated Other Comprehensive Income Employee	Accumulated Other Comprehensive Income Contractors	Accumulated Other Comprehensive Income Consultants	Accumulated Other Comprehensive Income	Employee	Contractors	Consultants	Total
Balance at Dec. 31, 2018				$ 106,392				$ 44,934				$ (131,256)				$ 1,243				$ 21,313
Balance (in shares) at Dec. 31, 2018				19,896
Stock options issued	$ 0	$ 0			$ 221	$ 43			$ 0	$ 0			$ 0	$ 0			$ 221	$ 43
Warrants issued to consultants			$ 0				$ 255				$ 0				$ 0				$ 255
Net (loss)				$ 0				0				(2,626)				0				(2,626)
Balance at Mar. 31, 2019				$ 106,392				45,453				(133,882)				1,243				19,206
Balance (in shares) at Mar. 31, 2019				19,896
Balance at Dec. 31, 2018				$ 106,392				44,934				(131,256)				1,243				21,313
Balance (in shares) at Dec. 31, 2018				19,896
Net (loss)																				(7,356)
Balance at Jun. 30, 2019				$ 106,392				47,453				(138,612)				1,243				16,476
Balance (in shares) at Jun. 30, 2019				19,896
Balance at Mar. 31, 2019				$ 106,392				45,453				(133,882)				1,243				19,206
Balance (in shares) at Mar. 31, 2019				19,896
Stock options issued	0	0			1,669	331			0	0			0	0			1,669	331
Net (loss)				$ 0				0				(4,730)				0				(4,730)
Balance at Jun. 30, 2019				$ 106,392				47,453				(138,612)				1,243				16,476
Balance (in shares) at Jun. 30, 2019				19,896
Balance at Dec. 31, 2019				$ 106,392				48,271				(144,031)				1,243				11,875
Balance (in shares) at Dec. 31, 2019				19,896
Stock options issued	0	0			391	21			0	0			0	0			391	21
Net (loss)				$ 0				0				(3,826)				0				(3,826)
Balance at Mar. 31, 2020				$ 106,392				48,683				(147,857)				1,243				8,461
Balance (in shares) at Mar. 31, 2020				19,896
Balance at Dec. 31, 2019				$ 106,392				48,271				(144,031)				1,243				11,875
Balance (in shares) at Dec. 31, 2019				19,896
Net (loss)																				(8,671)
Balance at Jun. 30, 2020				$ 138,359				49,226				(152,702)				1,243				36,126
Balance (in shares) at Jun. 30, 2020				25,356
Balance at Mar. 31, 2020				$ 106,392				48,683				(147,857)				1,243				8,461
Balance (in shares) at Mar. 31, 2020				19,896
Issuance of securities				$ 31,967				0				0				0				31,967
Issuance of securities (in shares)				5,460
Stock options issued	$ 0	$ 0			$ 522	$ 21			$ 0	$ 0			$ 0	$ 0			$ 522	$ 21
Net (loss)				$ 0				0				(4,845)				0				(4,845)
Balance at Jun. 30, 2020				$ 138,359				$ 49,226				$ (152,702)				$ 1,243				$ 36,126
Balance (in shares) at Jun. 30, 2020				25,356

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Nature of Business and Going Concern	6 Months Ended
Nature of Business and Going Concern	Jun. 30, 2020
Nature of Business and Going Concern
Nature of Business and Going Concern	1. Nature of Business and Going Concern Fennec Pharmaceuticals Inc. (“Fennec,” the “Company,” “we,” “us,” or “our”) is a biopharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric cancer patients. We incorporated under the Canada Business Corporations Act ("CBCA”) in September 1996. Effective on August 25, 2011, the Company continued from the CBCA to the Business Corporations Act (British Columbia) (the “Continuance”). The Continuance was approved by our shareholders at our June 2011 Annual and Special Meeting and by resolution of the Board of Directors on August 10, 2011. We have four wholly-owned subsidiaries: Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company and Fennec Pharmaceuticals (EU) Limited (“Fennec Limited”), an Ireland company formed in 2018. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive. These unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the three and six-months ended June 30, 2020, the Company incurred a loss from operations of $4,845 and $8,680, respectively. At June 30, 2020, it had an accumulated deficit of $152.7 million and had experienced negative cash flows from operating activities during the three and six-months ended June 30, 2020 in the amount of $3,116 and $6,865, respectively. On May 5, 2020, the Company announced the completion of an underwritten public offering of 4,800,000 common shares at a public offering price of $6.25 per share. In addition, Fennec issued an additional 660,204 common shares in connection with the partial exercise of the underwriters' over-allotment option. The approximate total gross proceeds from the offering was $34.1 million ($32.0 million net of commissions, fees and issue costs). On February 1, 2019, Fennec entered into a Loan and Security Agreement with Bridge Bank, a division of Western Alliance Bank, an Arizona corporation, pursuant to which the Bank agreed to loan $12.5 million to the Company, to be made available upon New Drug Application NDA approval of PEDMARK by no later than September 30, 2020. The proceeds from the loan will be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. Interest under the Term Loans shall bear interest, on the outstanding daily balance thereof, at a floating per annum rate equal to the Effective Interest Rate (as defined in the Loan and Security Agreement) which is equal to the sum of the Prime Rate published in the Wall Street Journal (currently 3.25%) plus one percent (1.00%). The debt facility is to have interest-only monthly payments due for the first eighteen months from the funding date and then monthly principal and interest payments are due through the remainder of the term which has a maturity date of October 1, 2023. In connection with the facility, Fennec granted Bridge Bank a warrant to purchase up to 39 common shares at an exercise price of $6.80 per common share, for a term of ten years from the date of issuance, subject to early termination under certain conditions. On June 26, 2020, Fennec announced an amendment to the Loan and Security Agreement with Bridge Bank. This amendment provides Fennec with an $18 million debt facility comprised of two term loans. Term Loan A consists of $12.5 million to be funded upon New Drug Application (NDA) approval of PEDMARKTM in the U.S. Term Loan B consists of $5.5 million to be funded upon the occurrence of a revenue event in 2021. The interest-only period for the facility has the ability to be extended from 18 months to 24 months from the funding of Term Loan A, provided that Term Loan B is funded, and certain conditions are met. The fee in connection with Loan B, can either be 2.13% of the Loan B amount in cash, or the Company can issue a warrant with a value equal to 3.25% of the Loan B amount. The Company has until August 6, 2020 to decide how to pay for the extended facility. These statements reflect the fee being settled with a warrant. Under Accounting Standards Codification ("ASC") 470-50, Modifications and Extinguishments, the amendment was considered a modification. As such, the Company is amortizing the loan fee and the value of the warrant over the remainder of the loan term. The Company intends to use the proceeds from the loans to provide working capital for commercialization activities for PEDMARKTM upon NDA approval. The Company believes the aforementioned debt facility, plus funds raised in the public offering which closed in May 2020, provides sufficient funding for the Company to carry-out its planned activities including NDA approval and the commencement of commercialization efforts for at least the next twenty months as it continues its strategic development of PEDMARKTM. These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.

Earnings per Share

6 Months Ended

Jun. 30, 2020

Earnings per Share

Earnings per Share

3. Earnings per Share

Earnings per common share is presented under two formats: basic earnings per common share and diluted earnings per common share. Basic earnings per common share is computed by dividing net income attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding during the period, plus the potentially dilutive impact of common stock equivalents (i.e. stock options and warrants). Dilutive common share equivalents consist of the incremental common shares issuable upon exercise of stock options and warrants. The following table sets forth the computation of basic and diluted net loss per share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Numerator:
Net (loss)	$	(4,845)	$	(4,730)	$	(8,671)	$	(7,356)

Denominator:
Weighted-average common shares, basic		23,393		19,896		21,635		19,896

Dilutive effect of stock options		—		—		—		—
Dilutive effect of warrants		—		—		—		—
Incremental dilutive shares		—		—		—		—

Weighted-average common shares, dilutive		23,393		19,896		21,635		19,896
Net (loss) per share, basic and diluted	$	(0.21)	$	(0.24)	$	(0.40)	$	(0.37)

The following outstanding options and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:


	Three Months Ended June 30,		Six Months Ended June 30,
	2020	2019	2020	2019
Options to purchase common stock	3,563	2,843	3,563	2,843
Warrants to purchase common stock	39	39	39	39

Stockholders' Equity

6 Months Ended

Jun. 30, 2020

Stockholders' Equity

Stockholders' Equity

4. Stockholders’ Equity

Authorized capital stock

The Company’s authorized capital stock consists of an unlimited number of shares of no-par common stock.

Warrants to Purchase Common Stock

During the three and six-months ended June 30, 2020, there were no warrants issued or exercised. During the three and six-months ended June 30, 2019, the Company issued warrants to purchase common stock priced in U.S. dollars with a weighted average price of $6.80. These warrants have not been exercised and have weighted average remaining life of 8.58 years as of June 30, 2020. The following table details the Company’s warrant activity from December 31, 2019:


	Common Shares Issuable Upon	Weighted-Average
Investor Warrants	Exercise of Outstanding Warrants	Exercise Price $USD
Outstanding December 31, 2019	39	6.80
Issued	—	—
Outstanding March 31, 2020	39	6.80
Issued	—	—
Outstanding June 30, 2020	39	6.80
Total	39	6.80


	Common Shares Issuable Upon	Weighted-Average
Investor Warrants	Exercise of Outstanding Warrants	Exercise Price $USD
Outstanding December 31, 2018	—	—
Issued	39	6.80
Outstanding March 31, 2019	39	6.80
Issued	—	—
Outstanding June 30, 2019	39	6.80
Total	39	6.80

The value of warrants issued was estimated using the Black-Scholes option pricing model using the following assumptions in the table below. The expected volatility was determined using historical volatility of our stock based on the contractual life of the award. The Company capitalized the non-cash expense of $179 associated with the anticipated issuance of warrants for the Loan B facility on August 6, 2020 and the $255 associated with issuing the above warrants on February 1, 2019. The Company also incurred legal, professional and share registration fees totaling $23 in 2020 and $71 in 2019 which were also capitalized. The combined capitalized asset, deferred issuance cost, has been placed on the balance sheet and is being amortized over the life of the loan facility.


	Valuation Assumptions
Black-Scholes Model Assumptions	February 1, 2019
Expected dividend	0.00	%
Risk free rate	2.70	%
Expected volatility	179	%
Expected life	10	years

Stock option plan

On June 22, 2020, shareholders of the Company approved a resolution adopting the Equity Incentive Plan (the "Plan"). This Plan replaces the Amended and Restated Stock Option Plan passed by shareholders in 2019. The Plan expands the types of instruments which may be issued as incentive compensation to employees, directors and designated contractors. In addition to stock options, the Plan may also issue: stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, cash-based awards and dividend equivalent rights. The Company believes this Plan gives it the ability to align incentives with strategic objectives.

The Compensation Committee of the Board of Directors administers the Company’s Plan. The Compensation Committee designates eligible participants to be included under the Plan and approves the number of options to be granted from time to time under the Plan. Currently, the maximum number of option shares issuable is twenty-five percent (25%) of the total number of issued and outstanding shares of common stock. Based upon the current shares outstanding, a maximum of 6,339 options are authorized for issuance under the Plan. For all options issued under the Plan, the exercise price is the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of ten years from the date of grant. The Plan allows the issuance of Canadian and U.S. dollar grants. The table below outlines recognized contractor and employee expense for the three and six-month periods ended June 30, 2020 and 2019.


	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Contractor options expense recognized	$	21	$	331	$	42	$	374
Employee options expense recognized		522		1,669		913		1,890
Total option expense recognized	$	543	$	2,000	$	955	$	2,264

Stock option activity

The following is a summary of option activity for each of the quarterly periods in fiscal year 2020 for stock options denominated in U.S. dollars:


	Number of	Weighted-Average
US Denominated Options	Options (thousands)	Exercise Price $USD
Outstanding December 31, 2019	2,440	$	3.59
Granted	—		—
Exercised	—		—
Outstanding at March 31, 2020	2,440	$	3.59
Granted	475		6.97
Outstanding at June 30, 2020	2,915	$	4.52

During the three-month period ended June 30, 2020, there were 475 US denominated options issued. Of the 2,915 US denominated options granted and outstanding at June 30, 2020, 2,023 are fully vested and exercisable.

The following is a summary of option activity for each of the quarterly periods in fiscal year 2019 for stock options denominated in U.S. dollars:


	Number of	Weighted-Average
US Denominated Options	Options (thousands)	Exercise Price $USD
Outstanding December 31, 2018	1,850	$	3.80
Granted	—		—
Exercised	—		—
Outstanding at March 31, 2019	1,850	$	3.80
Granted	345		4.69
Outstanding at June 30, 2019	2,195	$	3.94

The following is a summary of option activity for the three and six-month periods ended June 30, 2020 for stock options denominated in Canadian dollars:


	Number of	Weighted-Average
Canadian Denominated Options	Options (thousands)	Exercise Price $CAD
Outstanding December 31, 2019	648	$	2.43
Granted	—		—
Exercised	—		—
Outstanding at March 31, 2020	648	$	2.43
Granted	—		—
Exercised	—		—
Outstanding at June 30, 2020	648	$	2.43

For the three and six-month periods ended June 30, 2020, there was no issuance activity related to Canadian dollar denominated options. As of June 30, 2020, all 648 outstanding options denominated in Canadian dollars were fully vested and exercisable.

The following is a summary of option activity for the three and six-month periods ended June 30, 2019 for stock options denominated in Canadian dollars:


	Number of	Weighted-Average
Canadian Denominated Options	Options (thousands)	Exercise Price $CAD
Outstanding December 31, 2018	648	$	2.43
Granted	—		—
Exercised	—		—
Outstanding at March 31, 2019	648	$	2.43
Granted	—		—
Exercised	—		—
Outstanding at June 30, 2019	648	$	2.43

Valuation assumptions

The value of options granted were estimated using the Black-Scholes option pricing model using the following assumptions in the table below. The expected volatility was determined using historical volatility of our stock based on the contractual life of the award. There were 475 options issued during the three months ended June 30, 2020, (345 for the same period in 2019). Assumptions for the valuation of the option grants are described in the table below:


	Three Months Ended June 30,
Black-Scholes Model Assumptions	2020		2019
Expected dividend	0.00	%	0.00	%
Risk free rate	0.63 – 0.65	%	2.06 – 2.41	%
Expected volatility	143 – 144	%	136 – 156	%
Expected life	10 years		7 – 10 years

Fair Value Measurements

6 Months Ended

Jun. 30, 2020

Fair Value Measurements

Fair Value Measurements

5. Fair Value Measurements

The Company adopted the Fair Value Measurements and Disclosure Topic of the FASB in 2011. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Topic defines fair value, establishes a framework for measuring fair value in accordance with US GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.


	Fair Value Measurement at June 30, 2020 and December 31, 2019 (in thousands)
	Quoted Price in Active
	Market for Identical				Significant Other		Significant
	Instruments				Observable Inputs		Unobservable Inputs
	Level 1				Level 2		Level 3		Total
	2020		2019		2020	2019	2020	2019	2020	2019
Assets
Cash and cash equivalents	604	(1)	347	(1)	38,125	13,303	—	—	38,729	13,650

(1)

The Company held approximately, $604 in cash as of June 30, 2020, of which approximately, $34 was in Canadian funds (translated into U.S. dollars). As of December 31, 2019, the Company held approximately $347 of which approximately $30 was in Canadian funds (translated into U.S. dollars).

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2020
Commitments and Contingencies
Commitments and Contingencies	6. Commitments and Contingencies Oregon Health & Science University Agreement On February 20, 2013, Fennec entered into a new exclusive license agreement with OHSU for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including sodium thiosulfate and their use in oncology (the "OHSU Agreement"). OHSU will receive certain milestone payments, royalty on net sales for licensed products and a royalty on any consideration received from sublicensing of the licensed technology. On May 18, 2015, Fennec negotiated an amendment ("Amendment 1") to the OHSU Agreement, which expands Fennec's exclusive license to include the use of N-acetylcysteine as a standalone therapy and/or in combination with sodium thiosulfate for the prevention of ototoxicity induced by chemotherapeutic agents to treat cancers. Further, Amendment 1 adjusts select milestone payments entered in the OHSU Agreement including but not limited to the royalty rate on net sales for licensed products, royalty rate from sublicensing of the licensed technology and the fee payable upon the regulatory approval of a licensed product. The term of the OHSU Agreement as amended by Amendment 1 expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec or 8 years, whichever is later. In the event a licensed product obtains regulatory approval and is covered by the Orphan Drug Designation, the parties will in good faith amend the term of the agreement. Sodium thiosulfate is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe in 2021 and that expire in the United States in 2038. The OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec also has the right to terminate the OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the OHSU Agreement. Executive Severance In the event of his termination with us other than for cause, we will be obligated to pay Mr. Raykov a one-time severance payment equal to twelve months of salary (as of August 5, 2020 $430,000). In the event of his termination with us other than for cause, we will be obligated to pay Mr. Andrade a one-time severance payment equal to six months of salary (as of August 5, 2020 $155,875). In the event of her termination with us other than for cause, we will be obligated to pay Ms. Goel a one-time severance payment equal to three months of salary (as of August 5, 2020 $90,000) Leases We have an operating lease in Research Triangle Park, North Carolina utilizing small space within a commercial building. The operating lease has payments of $200 per month with no scheduled increases. This operating lease is terminable with 30 days’ notice and has no penalties or contingent payments due. On January 23, 2020, the Company entered into an Office Service Agreement (the "Office Service Agreement") with Regus to lease office space at in Hoboken, New Jersey. Per the terms of the Office Service Agreement, the monthly rent payments are $1,150. The Company was required to pay a security deposit of $2,300, which is the equivalent to two months of rent. The Office Service Agreement commenced on January 27, 2020 and terminates on July 31, 2020, thereafter the lease may continue on a month-to-month basis with either party being able to terminate the agreement by providing one months' advance written notice of termination. COVID-19 The Company's operations may be affected by the recent and ongoing outbreak of the coronavirus disease 2019 (COVID-19) which was declared a pandemic by the World Health Organization in March 2020. The ultimate disruption which may be caused by the outbreak is uncertain; however, it may result in a material adverse impact on the Company's financial position, operations and cash flows. Possible effects may include, but are not limited to, disruption to the Company's product launch which includes the ability of sales reps to communicate with oncologists, absenteeism in the Company's labor workforce, unavailability of products and supplies used in operations, and a decline in value of assets held by the Company, including inventories, property and equipment, and marketable securities. COVID-19 has not had a material effect on the Company's operations to date as the Company has historically had a workforce which works remotely, preparations for product launch have been under the assumption of a virtual launch and product supplies have not been impacted. Loan Security Agreement On February 1, 2019, the Company’s wholly owned subsidiary Fennec Pharmaceuticals Inc. entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Bridge Bank, a division of Western Alliance Bank, an Arizona corporation (the “Bank”), pursuant to which the Bank agreed to loan $12.5 million to Fennec Pharmaceuticals, Inc., to be made available upon New Drug Application (“NDA”) approval of PEDMARK by no later than September 30, 2020. The proceeds from the loan will be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. Interest under the Term Loans shall bear interest, on the outstanding daily balance thereof, at a floating per annum rate equal to the Effective Interest Rate (as defined in the Loan and Security Agreement) which is equal to the sum of the Prime Rate published in the Wall Street Journal (currently 3.25%) plus one percent (1.00%). The debt facility is to have interest-only monthly payments due for the first eighteen months from the funding date and then monthly principal and interest payments are due through the remainder of the term which has a maturity date of October 1, 2023. In connection with the facility, Fennec granted Bridge Bank a warrant to purchase up to 39 common shares at an exercise price of $6.80 per common share, for a term of ten years from the date of issuance, subject to early termination under certain conditions. On June 26, 2020, Fennec announced an amendment to the Loan and Security Agreement with Bridge Bank. This amendment provides Fennec with an $18 million debt facility comprised of two term loans. Term Loan A consists of $12.5 million to be funded upon New Drug Application (NDA) approval of PEDMARKTM in the U.S. Term Loan B consists of $5.5 million to be funded upon the occurrence of a revenue event in 2021. The interest-only period for the facility has the ability to be extended from 18 months to 24 months from the funding of Term Loan A, provided that Term Loan B is funded, and certain conditions are met. Under Accounting Standards Codification ("ASC") 470-50, Modifications and Extinguishments, the amendment was considered a modification. As such, the Company is amortizing the loan fee and the value of the warrant over the remainder of the loan term. The Company intends to use the proceeds from the loans to provide working capital for commercialization activities for PEDMARKTM upon NDA approval. The combined value of the granted warrants and the associated costs to secure the loan facility (approximately $528 thousand) were capitalized on the balance sheet as a long-term asset. The asset, deferred issuance cost, will be amortized evenly over the full term of the agreement (56 months). During the quarter ended June 30, 2020, the Company recorded amortization expense of roughly $30 as a result of the amortization of the asset related to deferred issuance cost. A total of $111 has been amortized as of June 30, 2020.

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Jun. 30, 2020
Significant Accounting Policies
Basis of presentation	Basis of presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with US GAAP and are the responsibility of the Company’s management. These unaudited interim condensed consolidated financial statements do not include all of the information and notes required by US GAAP for annual financial statements. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes filed with the Securities and Exchange Commission (“SEC”) in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2019. The Company’s accounting policies are consistent with those presented in the audited consolidated financial statements included in the Annual Report on Form 10‑K for the year ended December 31, 2019. These unaudited interim condensed consolidated financial statements have been prepared in U.S. dollars. All amounts presented are in thousands except for per share amounts.
Use of estimates	Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and the reported amounts of expense during the reporting period. Actual results could differ from those estimates. In the opinion of management, these unaudited interim condensed consolidated financial statements include all adjustments, which are normal and recurring in nature, necessary for the fair presentation of the Company’s financial position at June 30, 2020 and to state fairly the results for the periods presented. The most significant estimates utilized during the quarter ended June 30, 2020 included estimates necessary to value grants of stock options to employees and various contractors, disclosed in Note 4.
New accounting pronouncements	New accounting pronouncements In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 removes certain disclosures, modifies certain disclosures and adds additional disclosures. The ASU was effective for us on January 1, 2020, and interim periods within that fiscal year. Certain disclosures in ASU 2018-13 would need to be applied on a retrospective basis and others on a prospective basis. The Company concluded after evaluation, that the impact of ASU 2018-13 on our consolidated financial statements and disclosures was de minimis.
Cash and cash equivalents	Cash and cash equivalents Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At June 30, 2020, the Company had $38,729 in cash, savings and money market accounts ($13,650 at December 31, 2019). At June 30, 2020, the Company held $604 in cash of which $34 (as presented in U.S. dollars) was in Canadian dollars ($24 at December 31, 2019 as presented in U.S. dollars). At June 30, 2020, the Company held $38,125 in money market investments. Money market investments typically have minimal risks. The Company has not experienced any loss or write-down of its money market investments since inception.

Earnings per Share (Tables)

6 Months Ended

Jun. 30, 2020

Earnings per Share

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Numerator:
Net (loss)	$	(4,845)	$	(4,730)	$	(8,671)	$	(7,356)

Denominator:
Weighted-average common shares, basic		23,393		19,896		21,635		19,896

Dilutive effect of stock options		—		—		—		—
Dilutive effect of warrants		—		—		—		—
Incremental dilutive shares		—		—		—		—

Weighted-average common shares, dilutive		23,393		19,896		21,635		19,896
Net (loss) per share, basic and diluted	$	(0.21)	$	(0.24)	$	(0.40)	$	(0.37)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


	Three Months Ended June 30,		Six Months Ended June 30,
	2020	2019	2020	2019
Options to purchase common stock	3,563	2,843	3,563	2,843
Warrants to purchase common stock	39	39	39	39

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2020

Stockholders' Equity

Schedule of Warrants Outstanding to Purchase Common Stock

The following table details the Company’s warrant activity from December 31, 2019:


	Common Shares Issuable Upon	Weighted-Average
Investor Warrants	Exercise of Outstanding Warrants	Exercise Price $USD
Outstanding December 31, 2019	39	6.80
Issued	—	—
Outstanding March 31, 2020	39	6.80
Issued	—	—
Outstanding June 30, 2020	39	6.80
Total	39	6.80


	Common Shares Issuable Upon	Weighted-Average
Investor Warrants	Exercise of Outstanding Warrants	Exercise Price $USD
Outstanding December 31, 2018	—	—
Issued	39	6.80
Outstanding March 31, 2019	39	6.80
Issued	—	—
Outstanding June 30, 2019	39	6.80
Total	39	6.80


	Valuation Assumptions
Black-Scholes Model Assumptions	February 1, 2019
Expected dividend	0.00	%
Risk free rate	2.70	%
Expected volatility	179	%
Expected life	10	years

Schedule of Share Based Compensation, Stock Options Expense Recognized

The table below outlines recognized contractor and employee expense for the three and six-month periods ended June 30, 2020 and 2019.


	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Contractor options expense recognized	$	21	$	331	$	42	$	374
Employee options expense recognized		522		1,669		913		1,890
Total option expense recognized	$	543	$	2,000	$	955	$	2,264

Schedule of Share- Based Compensation Stock Options Activity

The following is a summary of option activity for each of the quarterly periods in fiscal year 2020 for stock options denominated in U.S. dollars:


	Number of	Weighted-Average
US Denominated Options	Options (thousands)	Exercise Price $USD
Outstanding December 31, 2019	2,440	$	3.59
Granted	—		—
Exercised	—		—
Outstanding at March 31, 2020	2,440	$	3.59
Granted	475		6.97
Outstanding at June 30, 2020	2,915	$	4.52

The following is a summary of option activity for each of the quarterly periods in fiscal year 2019 for stock options denominated in U.S. dollars:


	Number of	Weighted-Average
US Denominated Options	Options (thousands)	Exercise Price $USD
Outstanding December 31, 2018	1,850	$	3.80
Granted	—		—
Exercised	—		—
Outstanding at March 31, 2019	1,850	$	3.80
Granted	345		4.69
Outstanding at June 30, 2019	2,195	$	3.94

The following is a summary of option activity for the three and six-month periods ended June 30, 2020 for stock options denominated in Canadian dollars:


	Number of	Weighted-Average
Canadian Denominated Options	Options (thousands)	Exercise Price $CAD
Outstanding December 31, 2019	648	$	2.43
Granted	—		—
Exercised	—		—
Outstanding at March 31, 2020	648	$	2.43
Granted	—		—
Exercised	—		—
Outstanding at June 30, 2020	648	$	2.43

The following is a summary of option activity for the three and six-month periods ended June 30, 2019 for stock options denominated in Canadian dollars:


	Number of	Weighted-Average
Canadian Denominated Options	Options (thousands)	Exercise Price $CAD
Outstanding December 31, 2018	648	$	2.43
Granted	—		—
Exercised	—		—
Outstanding at March 31, 2019	648	$	2.43
Granted	—		—
Exercised	—		—
Outstanding at June 30, 2019	648	$	2.43

Schedule of assumptions for the valuation of the option grants

Assumptions for the valuation of the option grants are described in the table below:


	Three Months Ended June 30,
Black-Scholes Model Assumptions	2020		2019
Expected dividend	0.00	%	0.00	%
Risk free rate	0.63 – 0.65	%	2.06 – 2.41	%
Expected volatility	143 – 144	%	136 – 156	%
Expected life	10 years		7 – 10 years

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2020

Fair Value Measurements

Schedule of Assets/Liabilities Measured at Fair Value on Recurring Basis


	Fair Value Measurement at June 30, 2020 and December 31, 2019 (in thousands)
	Quoted Price in Active
	Market for Identical				Significant Other		Significant
	Instruments				Observable Inputs		Unobservable Inputs
	Level 1				Level 2		Level 3		Total
	2020		2019		2020	2019	2020	2019	2020	2019
Assets
Cash and cash equivalents	604	(1)	347	(1)	38,125	13,303	—	—	38,729	13,650

Nature of Business and Going Concern - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended				6 Months Ended
	Jun. 26, 2020	May 07, 2020	Feb. 01, 2019	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Going Concern [Line Items]
Loss from operations				$ (4,845)	$ (3,826)	$ (4,730)	$ (2,626)	$ (8,671)	$ (7,356)
Accumulated deficit				(152,702)				(152,702)		$ (144,031)
Cash flows from operating activities				$ (3,116)		$ (2,756)		$ (6,865)	$ (5,235)
Issuance of securities (in shares)		4,800,000
Shares issued, exercise price		$ 6.25
Total gross proceeds from the offering		$ 34,100
Net proceeds from public offering		$ 32,000
Overallotment Option
Going Concern [Line Items]
Issuance of securities (in shares)		660,204
Bridge Bank
Going Concern [Line Items]
Line of credit facility, borrowing capacity	$ 18,000
Bridge Bank \| Loan And Security Agreement \| Term Loan A
Going Concern [Line Items]
Shares issued, exercise price			$ 6.80
Line of credit facility, borrowing capacity			$ 12,500
Shares, issued			39,000
Debt instrument, variable interest rate			3.25%
Debt instrument, interest rate, stated percentage			1.00%
Bridge Bank \| Minimum
Going Concern [Line Items]
Line Of Credit Facility, Interest Only Period	18 months
Bridge Bank \| Maximum
Going Concern [Line Items]
Line Of Credit Facility, Interest Only Period	24 months
Bridge Bank \| Term Loan A
Going Concern [Line Items]
Line of credit facility, borrowing capacity	$ 12,500
Bridge Bank \| Term Loan A \| Minimum
Going Concern [Line Items]
Line Of Credit Facility, Interest Only Period	18 months
Bridge Bank \| Term Loan A \| Maximum
Going Concern [Line Items]
Line Of Credit Facility, Interest Only Period	24 months
Bridge Bank \| Term Loan B
Going Concern [Line Items]
Line of credit facility, borrowing capacity	$ 5,500
Line of Credit Facility, Commitment Fee Percentage	2.13%
Bridge Bank \| Term Loan B \| Warrants
Going Concern [Line Items]
Line of Credit Facility, Commitment Fee Percentage	3.25%

Earnings per Share - Computation of Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Numerator:
Net (loss)	$ (4,845)	$ (3,826)	$ (4,730)	$ (2,626)	$ (8,671)	$ (7,356)
Denominator:
Weighted-average common shares, basic	23,393		19,896		21,635	19,896
Incremental dilutive shares	0		0		0	0
Weighted-average common shares, dilutive	23,393		19,896		21,635	19,896
Net (loss) per share, basic and diluted	$ (0.21)		$ (0.24)		$ (0.40)	$ (0.37)
Warrants
Denominator:
Dilutive effect of stock options	0		0		0	0
Options
Denominator:
Dilutive effect of stock options	0		0		0	0

Stockholders' Equity - Summary of Option Activity (Details) - $ / shares shares in Thousands	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of Options Outstanding at Ending	475		345
Stock Option In Canadian Dollars [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of Options Outstanding at Beginning	648	648	648	648
Number of Options Granted	0	0	0	0
Number of Options Exercised	0	0	0	0
Number of Options Outstanding at Ending	648	648	648	648
Weighted-average Exercise Price outstanding at Beginning	$ 2.43	$ 2.43	$ 2.43	$ 2.43
Weighted-average Exercise Price Granted	0.00	0.00	0.00	0.00
Weighted-average Exercise Price Exercised	0.00	0.00	0.00	0.00
Weighted-average Exercise Price Outstanding at Ending	$ 2.43	$ 2.43	$ 2.43	$ 2.43
Stock Option In Us Dollars [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of Options Outstanding at Beginning	2,440	2,440	1,850	1,850
Number of Options Granted	475	0	345
Number of Options Exercised		0
Number of Options Outstanding at Ending	2,915	2,440	2,195	1,850
Weighted-average Exercise Price outstanding at Beginning	$ 3.59	$ 3.59	$ 3.80	$ 3.80
Weighted-average Exercise Price Granted	6.97	0	4.69
Weighted-average Exercise Price Exercised		0.00
Weighted-average Exercise Price Outstanding at Ending	$ 4.52	$ 3.59	$ 3.94	$ 3.80

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Aug. 06, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Feb. 01, 2019	Dec. 31, 2018
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.80	$ 6.80		$ 6.80	$ 6.80	$ 6.80
Debt Issuance Cost, Gross, Noncurrent	$ 528	$ 326
Shares issuable under Stock Option Plan, as percent of shares outstanding	25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	475				345
Stock Option In Canadian Dollars [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	648	648		648	648	648		648
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	648
Share Based Compensation Arrangement By Share Based Payment Award Options Issued Number	0
US Denominated [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	2,915
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	2,023
Share Based Compensation Arrangement By Share Based Payment Award Options Issued Number	475
U.S.dollars [Member]
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.80
Class Or Warrant Or Right Outstanding Weighted Average Remaining Contractual Terms	8 years 6 months 29 days
Consultants [Member]
Stockholders Equity Note [Line Items]
Debt Issuance Cost, Gross, Noncurrent			$ 179				$ 255
Payment For Legal Professional and Registration Fees Incurred For Warrant Issue Capitalize	$ 23	$ 71
Maximum
Stockholders Equity Note [Line Items]
Shares issuable under Stock Option Plan	6,339

Commitments and Contingencies (Details) - USD ($) $ / shares in Units, shares in Thousands				3 Months Ended		6 Months Ended
	Jun. 26, 2020	Jan. 23, 2020	Feb. 01, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	May 07, 2020	Dec. 31, 2019
Operating Leases, Rent Expense		$ 1,150,000				$ 200,000
Security Deposit Liability		$ 2,300,000
Duration Over Which The Costs Of Raising Finance Is To Be Amortized						56 months
Shares Issued, Price Per Share								$ 6.25
Amortization expense				$ 30,000	$ 17,000	$ 47,000	$ 29,000
Total amortization				111,000		111,000			$ 64,000
Term Loan A
Line of Credit Facility, Maximum Borrowing Capacity			$ 12,500,000
Debt Instrument, Basis Spread on Variable Rate			3.25%
Debt Instrument, Interest Rate, Stated Percentage			1.00%
Shares Issued, Price Per Share			$ 6.80
Shares, Issued			39
Warrants
Debt Issuance Costs, Noncurrent, Net				528,000		528,000
Bridge Bank
Line of Credit Facility, Maximum Borrowing Capacity	$ 18,000,000
Bridge Bank \| Minimum
Line Of Credit Facility, Interest Only Period	18 months
Bridge Bank \| Maximum
Line Of Credit Facility, Interest Only Period	24 months
Bridge Bank \| Term Loan A
Line of Credit Facility, Maximum Borrowing Capacity	$ 12,500,000
Bridge Bank \| Term Loan A \| Minimum
Line Of Credit Facility, Interest Only Period	18 months
Bridge Bank \| Term Loan A \| Maximum
Line Of Credit Facility, Interest Only Period	24 months
Bridge Bank \| Term Loan B
Line of Credit Facility, Maximum Borrowing Capacity	$ 5,500,000
Rostislav Raykov [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause				430,000		430,000
Robert Andrade [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause				155,875		155,875
Goel [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause				$ 90,000		$ 90,000

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2020
Subsequent Events
Subsequent Events	7. Subsequent Events Management has evaluated subsequent events through the date of this filing and concluded there are no events of significance which require disclosure.

Significant Accounting Policies - Additional Information (Details) $ in Thousands, $ in Thousands	Jun. 30, 2020 CAD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2019 CAD ($)	Dec. 31, 2019 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Money market investments		$ 38,729		$ 13,650
Cash	$ 34	604	$ 24
Money Market Funds
Summary Of Significant Accounting Policies [Line Items]
Money market investments		$ 38,125

Fair Value Measurements - Additional Information (Details) $ in Thousands, $ in Thousands	Jun. 30, 2020 CAD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2019 CAD ($)	Dec. 31, 2019 USD ($)
Fair Value Assets and Liabilities Measured On Recurring Basis [Line Items]
Cash	$ 34	$ 604	$ 24
Quoted Price in Active Markets for Identical Instruments Level 1 [Member]
Fair Value Assets and Liabilities Measured On Recurring Basis [Line Items]
Cash	$ 34	$ 604	$ 30	$ 347

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Jun. 30, 2020	Dec. 31, 2019
Condensed Consolidated Balance Sheets
Common stock, no par value	$ 0	$ 0
Common stock, shares issued	25,356	19,896
Common stock, shares outstanding	25,356	19,896

Stockholders' Equity - Black-Scholes option (Details)		3 Months Ended
Stockholders' Equity - Black-Scholes option (Details)	Feb. 01, 2019	Jun. 30, 2020	Jun. 30, 2019
Expected dividend	0.00%	0.00%	0.00%
Risk free rate	2.70%
Expected volatility	179.00%
Expected life	10 years	10 years
Minimum
Risk free rate		0.63%	2.06%
Expected volatility		143.00%	136.00%
Expected life			7 years
Maximum
Risk free rate		0.65%	2.41%
Expected volatility		144.00%	156.00%
Expected life			10 years

Fair Value Measurements - Assets/Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	$ 38,729	$ 13,650
Quoted Price in Active Markets for Identical Instruments Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	604	347
Significant Other Observable Inputs Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	38,125	13,303
Significant Unobservable Inputs Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	$ 0	$ 0